Cryoport(CYRX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Cryoport Reports Second Quarter 2024 Financial Results § Revenue improved sequentially across all businesses § Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially § A record total of 684 global clinical trials supported as of June 30, 2024 § Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025 § ...